-
Nomad Bioscience receives grants from Investment Bank Saxony-Anhalt for research on use of griffithsin and other plant lectins for prevention and therapy of SARS-CoV-2 infections
Nomad Bioscience GmbH was awarded two significant grants from Investment Bank Saxony-Anhalt (Investitionsbank Sachsen-Anhalt) for development of griffithsin and other plant-derived lectins as preventative therapies against coronaviruses. Lectins are sugar-binding proteins some of which effectively prevent attachment of enveloped viruses (such as coronaviruses, influenza viruses, immunodeficiency viruses) to human cells thus preventing viral infection. The aim of the studies is to produce recombinantly multiple lectins using Nomad’s rapid manufacturing platform Nomadic® and to evaluate their efficacy in vitro and in vivo as nasal/oral antiviral sprays. “Our main goal is to control coronavirus infection, although the same treatment may be effective also against other respiratory viruses such as influenza”, said Prof. Yuri Gleba, CEO of…
-
NOMAD Bioscience Published Milestone Paper in Nature Plants Describing its RNA-Based Rapid Transient Reprogramming of Crop Plants for Agronomic Performance
NOMAD Bioscience announces the publication in Nature Plants (Torti et al. (2021) Nature Plants 7; https://www.nature.com/articles/s41477-021-00851-y) a research paper describing NOMAD’s novel transient RNA replicon-based process of controlling agronomic performance of crop plants. The process does not involve genetic modification of the plant genome and is thus limited to a single plant generation, is broadly applicable, fast, tuneable, versatile, and can be used throughout much of the crop cultivation cycle. This alternative technology transiently targets various regulatory circuits within a plant, leading to operator-specified alterations of agronomic traits, such as time of flowering, vernalization requirement, plant height, drought tolerance, and many others. To use it on an industrial level, the…
-
NOMAD Bioscience Receives Its GRAS Regulatory Clearance In USA For Plant-Made Natural Thaumatin II As Flavour Modifier
NOMAD Bioscience GmbH received a formal ‘no questions’ letter from the US Food and Drug Administration (FDA) in response to NOMAD’s GRAS notice GRN 920 describing use of plant-produced Thaumatin II as flavour modifier. Thaumatin II is natural non-caloric high intensity sweetener and flavour modifier under development at NOMAD. GRAS is a facilitated US regulatory marketing allowance pathway for food substances and ingredients that are ‘Generally Recognized As Safe’ under conditions of intended use. The FDA’s response represents the eighth regulatory concurrence from the Agency in response to NOMAD’s GRAS submissions. Thaumatins are natural non-caloric sweeteners/flavour modifiers. Thaumatins are intensely sweet-tasting protein mixtures consisting mainly of Thaumatin I and Thaumatin…
-
NOMAD BIOSCIENCE Enters Into Agreement with CTAEX, Spain, To Conduct Its First Field Trials With Plants Producing Non-Caloric Sweetener Thaumatin II in Extremadura, Spain
NOMAD BIOSCIENCE GmbH, Munich, Germany (“NOMAD”) is pleased to announce that it has entered into a research and development agreement with CENTRO TECNOLOGICO NACIONAL AGROALIMENTARIO EXTREMADURA (“CTAEX”), Badajoz, Spain. In accordance with the Agreement, CTAEX is expected to conduct in 2021 first open field trials with NOMAD plant hosts expressing Thaumatin II, a natural high-intensity non-caloric sweetener of plant origin. The plant biomass will then be transported to a processing facility to purify quantities of Thaumatin II intended for NOMAD’s first consumer market studies in USA. Thaumatin II has received GRAS (Generally Recognized As Safe) status in USA (FDA GRN 738 and GRN 910) and it thus can be used…
-
NOMADS UAB, Lithuania, Receives a Research Grant from Lithuanian Business Support Agency LVPA
NOMADS UAB, Vilnius, Lithuania (“NOMADS”), a wholly owned subsidiary of Nomad Bioscience GmbH, Munich, Germany, is pleased to announce that the Company has been awarded a research grant from LVPA (Lietuvos Verslo Paramos Agentūra, Lithuanian Business Support Agency) to extend its exploration of antibacterial proteins for control of multi-drug and pan-drug resistant pathogenic bacteria Klebsiella and Pseudomonas. The grant covers multiple areas of research and early development of product candidates in NOMADS’ R&D pipeline, including, but not limited to, generation of different chimeric novel bacteriocins as well as in vitro and in vivo preclinical studies of the molecules. The grant provides NOMADS with access to external contract research organizations. “We are very pleased…
-
NOMAD Bioscience Receives Its GRAS Regulatory Clearance In USA For Plant-Made Natural Thaumatin II As Sweetener
NOMAD Bioscience received a formal ‘no questions’ letter from the US Food and Drug Administration (FDA) in response to NOMAD’s GRAS notice GRN 910 describing use of plant-produced Thaumatin II as sweetener. Thaumatin II is natural noncaloric high intensity sweetener under development at NOMAD. GRAS is a facilitated US regulatory marketing allowance pathway for food additives and ingredients that are ‘Generally Recognized As Safe’ under conditions of intended use. The FDA’s response represents the seventh regulatory concurrence from the Agency in response to NOMAD’s GRAS submissions, with one latest petition still pending. Thaumatins are natural non-caloric sweeteners/flavour modifiers. Thaumatins are intensely sweet-tasting protein mixtures (consisting mainly of Thaumatin I and…
-
Nomad Bioscience and Fraunhofer Institute for Cell Therapy and Immunology Enter into a Research and Development Agreement
Nomad Bioscience GmbH (“NOMAD”) is pleased to announce that the Company has entered into a broad research and development agreement with the Department of Drug Design and Target Validation of the Fraunhofer Institute for Cell Therapy and Immunology (Fraunhofer IZI), headquartered in Leipzig, Germany. The agreement covers multiple areas of research and early development of NOMAD’s R&D pipeline product candidates, including but not limited to, non-antibiotic antibacterial proteins bacteriocins for control of multi-drug and pan-drug resistant pathogenic Gram-negative bacteria (Klebsiella, Escherichia, Pseudomonas, Salmonella) as well as antiviral proteins lectins for prevention and early therapy of enveloped viruses such as includes coronaviruses, influenza viruses and human immunodeficiency viruses. The partnership provides NOMAD with…
